|Awarded On||February 16, 2022|
|Title||Targeting methylation-mediated mitotic fragility in ccRCC|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Ruhee Dere|
|Cancer Sites||Kidney and Renal Pelvis|
Clear cell renal cell carcinoma (ccRCC) is defined by two co-occurring genetic events, deletion of the short arm of chromosome 3p and gain of chromosome 5q, which results in loss of one copy of VHL, SETD2, PBRM1 and gain of NSD1. A subsequent deletion of the other copy of VHL drives oncogenesis. To date there is no common nuclear function that explains how these traditionally nuclear proteins drive cancer formation.
In exciting new data, we show an intersection of these proteins at structures involved in cell division (at mitotic spindles). ccRCC is not a tumor that is highly proliferative (undergoing lots of cell division) and therefore therapies targeting cell division have not been exte...